Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

新春佳节即将到来之际，南宁市多家医疗机构向全市人民送上诚挚的新春祝福。他们回顾过去一年在医疗技术、学科建设、服务提升等方面取得的丰硕成 果，展望新一年的发展规划与愿景，共同传递出守护人民健康、推动卫生健康事业高质量发展的坚定信念。 大家好！我是南宁市第四人民医院党委副书记、院长谢周华。 欢声辞旧岁，喜气迎马年。在此，我们向全市人民，以及所有关心支持医院工作的朋友们，致以诚挚的问候和美好的新春祝福！ 过去一年，南宁市第四人民医院用高标准党建引领高质量发展，医院门急诊综合大楼投入使用，改善了群众就医体验。三级甲等传染病专科医院复审通过， 医疗质量迈上更高台阶；成功应对基孔肯雅热疫情；获批成立"一带一路"真菌病国际联合实验室南宁分中心等。 新的一年，我们将继续恪尽职守，做好本职工作，守护人民健康。祝大家马年吉祥、身体健康、阖家幸福、万事如意！ 国医大师、广西中医药大学第一附属医院教授 黄瑾明 大家好！我是国医大师、广西中医药大学第一附属医院教授黄瑾明。 中医讲究"气血调和，阴阳平衡"，愿大家作息有常、饮食有节、情志舒畅，以健康的体魄迎接每一天。让我们传承养生智慧，共享安康岁月。 欢声辞旧岁，喜气迎马年！新的一年恭祝 ...

股票近期走势 近7天麦克森股价波动显著。2026年2月5日，股价单日大涨16.52%至957.80美元，成交额达21.35亿美 元；2月6日微跌0.95%至948.68美元；2月9日反弹1.44%至962.32美元；2月10日受大盘情绪影响回调 2.82%至935.21美元；最新数据显示，2月11日收盘价为953.02美元，日涨幅1.90%。近5日累计涨幅为 15.94%，年初至今上涨16.18%。 机构观点 经济观察网麦克森于2026年2月4日公布2026财年第三季度财报，业绩超预期，带动股价显著波动，并引 发多家华尔街机构集中更新评级。全球市场避险情绪对医疗板块影响有限，麦克森因业绩稳健表现相对 抗跌。 多家华尔街机构于2026年2月5日至6日更新评级。TD Cowen维持买入评级，目标价从1000美元上调至 1012美元；富国集团将目标价上调至925美元；Evercore维持1000美元目标价；瑞穗证券目标价上调至 885美元；贝雅目标价上调至974美元。当前机构目标均价为980.47美元，较最新股价有潜在上行空间。 财报分析 以上内容基于公开资料整理，不构成投资建议。 麦克森2026财年第三季度营业收 ...

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 4.8555 million shares on February 11, with a total net reduction of 5.5385 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds increased their holdings on 14 days, resulting in a cumulative net increase of 19.0741 million shares [1] - As of now, southbound funds hold 1.466 billion shares of Jinxin Reproductive Medicine, accounting for 53.15% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, and maternal and pediatric medical services, as well as the sale of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Core Viewpoint - Southbound funds have increased their holdings in China Silicon Corporation (01735.HK) by 2.597 million shares on February 11, indicating a positive trend in investor sentiment towards the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 8.277 million shares [1] - In the last twenty trading days, there have been fifteen days of net increases, totaling 21.701 million shares [1] - Currently, southbound funds hold 15.2 million shares of China Silicon Corporation, representing 3.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - China Silicon Corporation, formerly known as China Silicon Holdings Group Limited, is primarily engaged in the renewable energy and engineering, procurement, and construction (EPC) business [1] - The company operates through five business segments, including renewable energy and engineering, green building and related services, health and medical services, food supply chain services, and smart energy management services [1] - The renewable energy and engineering segment focuses on the production and sales of photovoltaic products, while the green building segment provides construction and property management services [1]

Core Viewpoint - Southbound funds reduced their holdings in Haijia Medical (06078.HK) by 122,800 shares on February 11, while in the past five trading days, there were four days of net increases totaling 1,164,800 shares [1] Group 1: Southbound Fund Activity - In the last 20 trading days, southbound funds have reduced their holdings on 12 days, with a total net reduction of 3,828,600 shares [1] - Currently, southbound funds hold 203 million shares of Haijia Medical, accounting for 32.83% of the company's issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments: the hospital business segment focuses on providing comprehensive diagnosis and treatment services for tumors, including multiple cancer medical services such as radiotherapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is engaged in various other operations, with the company primarily operating in the domestic market [1]

经济观察网截至2026年2月11日，Akso Health Group(AHG.OQ)近7天股价呈现下行趋势，区间累计跌幅 达9.38%，振幅12.50%。2月11日收盘价1.45美元，单日持平，但5日跌幅为9.69%。成交持续清淡，日均 成交额仅约5000美元，反映市场流动性较低。 财报分析 公司2025财年年报(截至2025年3月31日)显示，营收同比大幅增长513.54%至1479.53万美元，但净亏损扩 大至1.35亿美元，毛利率为-1.91%，主因销售成本占比过高。当前市销率达22.93倍，高于行业均值，财 务压力仍存。 以上内容基于公开资料整理，不构成投资建议。 ...

Financial Data and Key Metrics Changes - The company reported net operating revenues of $21.3 billion for 2025, with consolidated adjusted EBITDA of $4.57 billion, representing a 14% growth over 2024 [5][13] - The adjusted EBITDA margin for the full year was 21.4%, an improvement of 210 basis points from the prior year [14] - In Q4 2025, total net operating revenues were $5.5 billion, with consolidated adjusted EBITDA of $1.183 billion, a 13% increase year-over-year [12] Business Line Data and Key Metrics Changes - The USPI segment's adjusted EBITDA grew 12% in 2025 to $2.026 billion, with same-facility revenues increasing by 7.2% [6][14] - The hospital segment's adjusted EBITDA increased by 16% to $2.54 billion, with same-store revenues per adjusted admission up 5.3% [7][14] - Same facility revenues grew 7.5%, driven by double-digit growth in total joint replacements in ASCs [7] Market Data and Key Metrics Changes - The company experienced strong same-store revenue growth, exceeding the long-term goal of 3%-6% organic growth [7] - The company anticipates a 20% reduction in overall enrollment due to the expiration of enhanced premium tax credits, which may impact the hospital segment significantly [10][11] Company Strategy and Development Direction - The company plans to continue focusing on organic growth supplemented by accretive M&A, particularly in the USPI segment, with a target of $250 million in annual M&A [8][22] - The company is also investing in technology and operational efficiencies to enhance expense management and improve clinical throughput [28][45] - The company aims to leverage its capabilities to serve patients better and expand service lines, particularly in high acuity areas [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong core earnings growth for 2026, despite anticipated headwinds from the expiration of enhanced premium tax credits [11][19] - The company expects adjusted EBITDA for 2026 to be in the range of $4.485 billion to $4.785 billion, driven by ongoing demand and acuity [9][18] - Management highlighted the importance of monitoring enrollment levels and effectuation rates as they navigate the changing healthcare landscape [11][72] Other Important Information - The company repurchased approximately 22% of its outstanding shares for around $2.5 billion since the share repurchase program began in Q4 2022 [8] - The company generated $367 million of free cash flow in Q4 2025, totaling $2.53 billion for the full year [15] Q&A Session Summary Question: Can you expand on the same-store hospital volume performance in the quarter? - Management noted that while acuity was good, the respiratory season was weaker than expected, impacting volumes [25] Question: What do you mean by tackling expense management more structurally? - Management explained that they are focusing on technology deployment for sustainable expense reduction, including automation and clinical throughput improvements [27][28] Question: Can you provide more details on the hospital admission growth guidance of 1%-2%? - Management indicated that the guidance reflects anticipated impacts from exchange exposure and investments in higher acuity capabilities [32] Question: Is the growth type sustainable in future years? - Management believes that while achieving 10% growth is ambitious, their track record of acuity growth and margin expansion supports this outlook [39][40] Question: What is the payer mix for USPI in Q4? - Management reported a consistent payer mix with net revenue per case growth of 5.5% and EBITDA margins above 40% [84]

近期事件 经济观察网 麦克森于2026年2月4日发布2026财年第三季度财报（截至2025年12月31日）。根据财报数 据，季度营业收入为1061.58亿美元，同比增长11.40%；归母净利润为11.86亿美元，同比增长34.93%； 净利率为1.12%。公司同时上调了全年每股收益指引，反映出对业务增长的信心。肿瘤与多专科业务表 现亮眼，收入同比增长31.5%，成为关键增长引擎。 机构观点 多家华尔街机构近期更新对麦克森的评级。TD Cowen于2026年2月5日维持买入评级，并将目标价从 1000美元上调至1012美元。富国集团、Evercore、瑞穗证券和贝雅等机构在2月6日集中调整目标价，区 间为885美元至1000美元，其中Evercore维持1000美元的最高目标价。当前机构目标均价为980.47美元， 较最新股价有潜在上行空间。 股票近期走势 近7天麦克森股价波动显著。2026年2月5日，股价单日大涨16.52%至957.80美元，成交额达21.35亿美 元，显示市场对财报的积极反应；2月6日股价微跌0.95%，但成交额仍维持11.28亿美元的高位；2月9日 股价反弹1.44%至962.32美元； ...

GUANZE MEDICAL(02427)及要约人富德(香港)投资控股有限公司联合公布，董事会获售股股东告知， 于2026年1月28日，要约人(作为买方)与售股股东Meng A Capital Limited(作为卖方)订立买卖协议，以向 售股股东收购6.99亿股股份，占本公司于本联合公告日期已发行股本总数约73.60%，总代价为1.75亿港 元(相当于代价每股股份0.25港元)。 此外，本公司已向联交所申请股份自2026年2月12日(星期四)上午九时正起恢复买卖。 要约价每股要约股份0.25港元，较在最后交易日(即2026年1月26日)于联交所所报收市价每股股份1.560 港元折让约84.0%。 要约人为一间于2015年9月17日在香港注册成立的有限责任公司，主要从事股票及股权投资。于本联合 公告日期，要约人由张峻先生(张先生)及陶美萦女士(陶女士)分别最终实益拥有94%及6%。于本联合公 告日期，要约人由富德控股(集团)有限公司(一间于中国成立的公司)直接全资拥有，而富德控股(集团)有 限公司则由深圳市峻德投资有限公司(一间于中国成立的公司)(由张先生全资拥有)、张先生、深圳市富 源祥投资有限公司(一间于 ...